Year: 2024
Type: dissertation
Abstract: Controlling and eliminating infections such as those caused by the Hepatitis B virus, Hepatitis C virus, and Human Immunodeficiency Virus are priority objectives for the World Health Organization. Drug users constitute a particularly vulnerable population for acquiring these infections. The psychosocial problems stemming from drug consumption and stigma act as barriers that impede drug users' access to healthcare services and their engagement with them. This often leads to delayed diagnosis of these infections, treatment delays, and frequent interruptions and discontinuations of treatment. Consequently, there are two significant consequences: high morbidity and mortality rates from these infections among drug users and drug users serving as reservoirs for these infections. Therefore, addressing viral infections in drug users presents a challenge that involves improving the individual health of each patient and achieving infection control within this group to prevent its spread to the general population. The burden of hepatitis C infection in people with a history of current drug use is a high risk of hepatic complications and transmission of infectious disease. This population is poorly linked to the health system, and it is difficult to achieve and support treatment because they have high rates of lost follow-up. We evaluate an intervention for the diagnosis and treatment of chronic hepatitis C and HIV in this population. Six hundred and eighty-three people attended the DAC and were asked to participate in health counseling and provide blood samples for testing HCV, HIV, and syphilis from April 2019 to June 2020. A total of 556 subjects were surveyed and tested. All of them were assigned to a patient navigation program to improve health education and link to the sanitary system. Of the 556 patients who agreed to participate in the study, 33 (5.9%) had active HCV infection. Twenty-eight patients (93.3%) completed treatment, and 26 achieved Sustained Viral Response (78.8%). Our study suggests that implementing strategies based on personalized intervention models can contribute to controlling HCV infection in DAC users. Persons with substance use disorder are at increased risk for hepatitis B virus (HBV) infection. Although most of them are attached to social health centers, the vaccination rate in this group is low. In this context, we designed a study to evaluate the prevalence of users of drug addiction centers (DAC) not immunized against hepatitis B and to compare the vaccination rate against hepatitis B with the rate of immunization against SARS-Cov-2 in two years of follow-up. A total of 325 subjects were surveyed and tested. At baseline, 65% (211/325) were candidates to initiate vaccination and were advisors to HBV vaccination. During the follow-up, 15/211 (7,2%) individuals received at least one dose of HBV vaccine. In the same period, 186/211 (88,2%) individuals received at least one dose against SARS-Cov-2. The comparison between vaccination rates reached statistically significant (p < 0.001). Our study manifests a low immunization rate against HBV in DAC users despite a high level of immunization for SARS-Cov-2 during the same period in the same population. Consequently, the lack of immunization against HVB in this population might be related to health policy issues more than to individuals linked to care and awareness. Late presentation of HIV infection, defined by the presence of a CD4 + cell count < 200 cells/mm3 or AIDS-defining conditions (a widespread situation among drug users), remains a significant problem among people living with HIV. We assess the effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in late presenter treatment-naïve adult individuals from the CoRIS Cohort. The primary objective was the achievement of viral suppression (VS), defined as HIV RNA < 50 cop/mL. We evaluated 314 individuals. Individuals with AIDS-defining conditions initiating ART with BIC/FTC/TAF achieved higher rates of viral suppression at 24 weeks than other regimens. At 24 and 48 weeks after ART initiation, treatment discontinuations were lower with BIC/FTC/TAF than with other regimens. Our results suggest that BIC/FTC/TAF could be a preferred regimen as initial therapy in HIV late presenters because of its high effectiveness and good tolerability.
Author: Corona Mata, Diana
Language: English
Topic: HIV, Drug Use, Sexual Risk
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7033132833
